Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Transl Lung Cancer Res
2020 Dec 01;96:2521-2534. doi: 10.21037/tlcr-20-331.
Show Gene links
Show Anatomy links
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
Xia B
,
Nagasaka M
,
Zhu VW
,
Ou SI
,
Soo RA
.
???displayArticle.abstract???
Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor was approved. Since then, subsequent generations of ALK inhibitors have demonstrated superior efficacy and better CNS activity compared to crizotinib. Alectinib and brigatinib, both second-generation ALK inhibitors have been compared directly to crizotinib in the first-line setting and has demonstrated improved progression free survival (PFS) and intracranial response. Ceritinib, another second-generation ALK inhibitor has been shown to be superior to chemotherapy in ALK-rearranged disease with good CNS activity. Initial responses to ALK inhibitors are not always durable and resistance can occur as on-target or off-target alterations. Lorlatinib, a third-generation ALK inhibitor, has demonstrated activity in the treatment naïve setting and in resistance to crizotinib and second-generation ALK inhibitors. Lorlatinib has also shown improved PFS in patients harboring EML4-ALK variant 3, which is associated with the development of ALK resistance mutations, specifically G1202R. Another new ALK inhibitor, ensartinib, has demonstrated efficacy in the first-line setting and in alectinib refractory disease. Additional studies are underway examining mechanisms of resistance and best treatment options post resistance.
Bauer,
Clinical Management of Adverse Events Associated with Lorlatinib.
2019, Pubmed
Bauer,
Clinical Management of Adverse Events Associated with Lorlatinib.
2019,
Pubmed
Bray,
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
2018,
Pubmed
Burudpakdee,
Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
2018,
Pubmed
Camidge,
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
2018,
Pubmed
Camidge,
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
2019,
Pubmed
,
Echinobase
Chiari,
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
2015,
Pubmed
Cho,
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
2017,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Costa,
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
2015,
Pubmed
Costa,
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
2011,
Pubmed
Duruisseaux,
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
2017,
Pubmed
Felip,
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
2020,
Pubmed
,
Echinobase
Gadgeel,
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
2018,
Pubmed
Gainor,
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
2016,
Pubmed
Gainor,
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
2015,
Pubmed
Gainor,
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
2016,
Pubmed
Hida,
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
2017,
Pubmed
Hida,
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
2018,
Pubmed
Horn,
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
2018,
Pubmed
Horn,
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
2019,
Pubmed
Horn,
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
2009,
Pubmed
Hrustanovic,
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
2015,
Pubmed
Iams,
Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
2015,
Pubmed
Ito,
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
2017,
Pubmed
Lin,
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
2018,
Pubmed
Lin,
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
2018,
Pubmed
Lin,
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.
2020,
Pubmed
Neuvonen,
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
2006,
Pubmed
Ou,
Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020.
2020,
Pubmed
Ou,
Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
2016,
Pubmed
Ou,
Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
2015,
Pubmed
Peters,
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
2017,
Pubmed
Pikor,
Genetic alterations defining NSCLC subtypes and their therapeutic implications.
2013,
Pubmed
Rangachari,
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
2015,
Pubmed
Rolfo,
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
2018,
Pubmed
Sasaki,
The biology and treatment of EML4-ALK non-small cell lung cancer.
2010,
Pubmed
,
Echinobase
Shaw,
Targeting anaplastic lymphoma kinase in lung cancer.
2011,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
Ceritinib in ALK-rearranged non-small-cell lung cancer.
2014,
Pubmed
Shaw,
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
2017,
Pubmed
Shaw,
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
2019,
Pubmed
Shaw,
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
2016,
Pubmed
Solomon,
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
2018,
Pubmed
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Soria,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
2017,
Pubmed
Spigel,
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
2018,
Pubmed
Syed,
Lorlatinib: First Global Approval.
2019,
Pubmed
Weickhardt,
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
2012,
Pubmed
Yoda,
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
2018,
Pubmed
Yoshida,
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
2016,
Pubmed
Zhou,
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
2019,
Pubmed
Zhou,
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
2018,
Pubmed
Zhu,
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases.
2020,
Pubmed
